Want to see TSE:THRM full AI Analyst Report?
THRM Stock Chart & Stats
C$0.06
>-C$0.01(-12.50%)
At close: 4:00 PM EST
C$0.06
>-C$0.01(-12.50%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.12
Previous CloseN/A
Volume10.00K
Average Volume (3M)50.06K
Market Cap
C$2.90M
Enterprise ValueC$2.93M
Total Cash (Recent Filing)C$25.13K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding61,246,628
10 Day Avg. Volume51,225
30 Day Avg. Volume50,057
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.51
Price to Sales (P/S)48.92
P/FCF Ratio-26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginA sharp TTM revenue rebound combined with a ~49% gross margin indicates improving product-market fit or better pricing/mix and meaningful gross-profit recovery. Sustained revenue growth at healthy gross margins is a durable path to operating leverage if variable costs remain controlled.
Low Absolute DebtVery low absolute debt reduces near-term refinancing and interest-cost risk, giving management flexibility to prioritize operational improvements or strategic investments. For a small medical-device developer, low leverage is a structural strength versus highly indebted peers.
Narrowing Cash Burn TrendImproving cash burn and positive free-cash-flow growth trends indicate management is narrowing losses and improving cash conversion. If these operational improvements persist, they materially reduce near-term funding needs and increase the probability of reaching sustainable operations over months.
Bears Say
Large Net LossesA ~-4.0M TTM net loss is structurally large relative to current revenues (~136K TTM), signaling prolonged unprofitability. Large recurring losses erode capital, necessitate external financing or dilution, and limit the company’s ability to reinvest in R&D, commercialization, or scale over the medium term.
Negative Stockholders' EquityNegative shareholders' equity (~-1.9M) reflects accumulated losses that have depleted the capital base. This weakens borrowing capacity, complicates commercial partnerships or supplier credit, and is a persistent structural balance-sheet constraint unless reversed by profitable operations or recapitalization.
Operating Cash Flow Still NegativeOngoing negative operating and free cash flow (~-217K TTM) means the business still requires external funding to operate. Even with improvement, persistent negative OCF constrains investment in sales and product development and increases timing risk around capital raises over the next several months.
Therma Bright News
THRM FAQ
What was Therma Bright’s price range in the past 12 months?
Therma Bright lowest stock price was C$0.04 and its highest was C$0.12 in the past 12 months.
What is Therma Bright’s market cap?
Therma Bright’s market cap is C$2.90M.
When is Therma Bright’s upcoming earnings report date?
Therma Bright’s upcoming earnings report date is Dec 01, 2026 which is in 152 days.
How were Therma Bright’s earnings last quarter?
Therma Bright released its earnings results on Jun 25, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Therma Bright overvalued?
According to Wall Street analysts Therma Bright’s price is currently Overvalued.
Does Therma Bright pay dividends?
Therma Bright does not currently pay dividends.
What is Therma Bright’s EPS estimate?
Therma Bright’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Therma Bright have?
Therma Bright has 61,246,628 shares outstanding.
What happened to Therma Bright’s price movement after its last earnings report?
Therma Bright reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Therma Bright?
Currently, no hedge funds are holding shares in TSE:THRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Therma Bright
Established in Toronto, Canada, in 2001 as The Jenex Corporation before rebranding to Therma Bright Inc. in February 2018, Therma Bright Inc. specializes in creating and distributing various medical and consumer health products. Their diverse offerings include rapid COVID-19 diagnostic tests like AcuVid, which screens for both antigens and antibodies. For pain relief, they provide devices such as Benepod, a hot and cold contrast therapy system designed to manage discomfort without medication. The company also addresses circulatory issues with Venowave, a medical compression pump aimed at mitigating symptoms associated with poor circulation. Furthermore, Therma Bright caters to the cosmeceutical industry with products like InterceptCS, a cold sore prevention system utilizing safe, controlled topical heat, and TherOZap, a thermal device that alleviates the pain, itching, and inflammation from insect bites and stings by reducing the inflammatory response. Their clientele spans both individual consumers and healthcare practitioners.
Technical Analysis
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―
Options Prices
Currently, No data available
---